HPV vaccines: how many doses are needed for protection?
作者： Margaret Stanley
关键词:
摘要: HPV virus-like particle vaccines are highly immunogenic, well tolerated and in the national immunization programs more than 62 countries. Genital is a sexually transmitted infection with first occurring just after onset of sexual activity. The routine cohort for almost all countries adolescent girls 9–15 years age or without catch-up older adolescents young women. In vaccine coverage exceeding 50%, reductions type geno-prevalence disease being shown. mechanism protection assumed to be via neutralizing antibody. Antibody concentration less 14 two doses at 0 6 months noninferior women three whom efficacy was demonstrated randomized control trials. original three-dose schedules have already been reduced many countries, those under, least apart licensed vacc...
futuremedicine.com
sci-hub.se 参考文章(79)
S. Longet, J. T. Schiller, M. Bobst, P. Jichlinski, D. Nardelli-Haefliger, A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. Journal of Virology. ,vol. 85, pp. 13253- 13259 ,(2011) , 10.1128/JVI.06093-11
J. A. Suzich, S. J. Ghim, F. J. Palmer-Hill, W. I. White, J. K. Tamura, J. A. Bell, J. A. Newsome, A. B. Jenson, R. Schlegel, Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas Proceedings of the National Academy of Sciences of the United States of America. ,vol. 92, pp. 11553- 11557 ,(1995) , 10.1073/PNAS.92.25.11553
Birgitte Baldur-Felskov, Christian Dehlendorff, Jette Junge, Christian Munk, Susanne K. Kjaer, Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes & Control. ,vol. 25, pp. 915- 922 ,(2014) , 10.1007/S10552-014-0392-4
K G J Pollock, K Kavanagh, A Potts, J Love, K Cuschieri, H Cubie, C Robertson, M Cruickshank, T J Palmer, S Nicoll, M Donaghy, Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland British Journal of Cancer. ,vol. 111, pp. 1824- 1830 ,(2014) , 10.1038/BJC.2014.479
Ethel-Michele de Villiers, Cross-roads in the classification of papillomaviruses Virology. ,vol. 445, pp. 2- 10 ,(2013) , 10.1016/J.VIROL.2013.04.023
John Doorbar, Wim Quint, Lawrence Banks, Ignacio G. Bravo, Mark Stoler, Tom R. Broker, Margaret A. Stanley, The biology and life-cycle of human papillomaviruses. Vaccine. ,vol. 30, ,(2012) , 10.1016/J.VACCINE.2012.06.083
Mathieu Boxus, Laurence Lockman, Michel Fochesato, Clarisse Lorin, Florence Thomas, Sandra L. Giannini, Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine. ,vol. 32, pp. 3232- 3236 ,(2014) , 10.1016/J.VACCINE.2014.04.005
Margaret Stanley, Ligia A. Pinto, Connie Trimble, Human papillomavirus vaccines--immune responses. Vaccine. ,vol. 30, ,(2012) , 10.1016/J.VACCINE.2012.04.106
Ali Rowhani-Rahbar, Constance Mao, James P. Hughes, Frances B. Alvarez, Janine T. Bryan, Stephen E. Hawes, Noel S. Weiss, Laura A. Koutsky, Longer-term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine Vaccine. ,vol. 27, pp. 5612- 5619 ,(2009) , 10.1016/J.VACCINE.2009.07.027
Sarah L Osborne, Sepehr N Tabrizi, Julia ML Brotherton, Alyssa M Cornall, John D Wark, C David Wrede, Yasmin Jayasinghe, Dorota M Gertig, Marian K Pitts, Suzanne M Garland, Vaccine Study Group, Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program Vaccine. ,vol. 33, pp. 201- 208 ,(2015) , 10.1016/J.VACCINE.2014.10.045